|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 35/17 | (2015.01) |
| A61K 35/17 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| C12N 5/0781 | (2010.01) | ||
| C12N 5/0635 | (2013.01) | ||
| C12N 5/0783 | (2010.01) | ||
| C12N 5/0636 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C12N2501/2302 | (2013.01) | ||
| C12N2501/2315 | (2013.01) | ||
| C12N2501/2321 | (2013.01) | ||
| C12N2501/515 | (2013.01) | ||
| C12N2502/11 | (2013.01) | ||
| C12N 5/0638 | (2013.01) |
| (11) | Patento numeris | 3843759 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19856433.8 |
| Europos patento paraiškos padavimo data | 2019-09-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2021-07-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2024-02-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2019/049384 |
| Data | 2019-09-03 |
| (87) | Numeris | WO 2020/096682 |
| Data | 2020-05-14 |
| (30) | Numeris | Data | Šalis |
| 201862725976 P | 2018-08-31 | US | |
| 201862726919 P | 2018-09-04 | US |
| (72) |
FARDIS, Maria , US
NATARAJAN, Arvind , US
|
| (73) |
Iovance Biotherapeutics, Inc. ,
825 Industrial Road
Suite 400, San Carlos, CA 94070,
US
|
| (54) | USE OF TUMOR INFLITRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY |
| USE OF TUMOR INFILTRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY |